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Summary: 45 
Anti-obesity drugs in the amphetamine (AMPH) class act in the brain to reduce appetite and 46 
increase locomotion. They are also characterized by adverse cardiovascular effects with origin 47 
that, despite absence of any direct in vivo evidence, is empirically attributed to a peripheral 48 
sympathomimetic action in the heart. Here, we show that the cardiac side effects of AMPH 49 
originate in the brain and can be circumvented by PEGylation (PEGyAMPH) to exclude its central 50 
action. PEGyAMPH does not enter the brain and facilitates SNS activity via the 2 adrenergic 51 
receptor, protecting mice against obesity by increasing lipolysis and thermogenesis, coupled to 52 
higher heat-dissipation which acts as an energy sink to increase energy expenditure without 53 
altering food intake or locomotor activity. Thus, we provide proof-of-principle for a novel class of 54 
exclusively peripheral anti-obesity sympathofacilitators that are devoid of cardiovascular and 55 
brain-related side effects.  56 
Keywords:  57 
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Highlights:  60 
 PEGylated amphetamine (PEGyAMPH) is a first-in-class anti-obesity sympathofacilitator, 61 
acting via the 2 adrenergic receptor. 62 
 PEGyAMPH increases EE and weight loss, by coupling thermogenesis to heat-dissipation. 63 
 PEGyAMPH does not enter the brain, nor has behavioural effects 64 
 PEGyAMPH is cardioprotective, unless directly delivered into the brain 65 
 66 
 67 
Introduction:  68 
Anti-obesity drugs in the amphetamine (AMPH) class, such as FDA-approved phentermine, are 69 
highly efficacious therapeutic compounds approved for common obesity (Cooke and Bloom, 70 
2006; Melnikova and Wages, 2006). The potent anti-obesity effects of this class of drugs are 71 
reported to be mediated by a stimulant action in the brain that supresses appetite and promotes 72 
hyperkinesia (Cooke and Bloom, 2006; Heal et al., 2013; Melnikova and Wages, 2006). Although 73 
the anti-obesity effects of AMPH are unparalleled, these drugs are not only addictive, they also 74 
drive cardiovascular side effects such as tachycardia and hypertension. It is insofar unclear 75 
whether the cardiac side effects of AMPHs originate peripherally or centrally in the brain. Central 76 
action is a viable possibility, as the brain robustly controls heart rate and vascular capacitance in 77 
response to multiple internal and external stimuli (Malpas, 2010). However, despite the lack of 78 





Specifically, no direct evidence exists regarding the in vivo origin of cardiovascular side effects 80 
and whether a cardioneutral anti-obesity effect could result if AMPH is excluded from the brain. 81 
All AMPHs are coined as indirect sympathomimetics because they block monoamine transporters 82 
thus increasing catecholamine availability (Cooke and Bloom, 2006; Heal et al., 2013; Melnikova 83 
and Wages, 2006). Recent evidence demonstrates that genetic loss-of-function of norepinephrine 84 
(NE) transporter (Slc6a2) outside the brain is sufficient for weight loss, without changes in food 85 
intake or locomotor activity (Pirzgalska et al., 2017). As such, we hypothesized that preventing 86 
access of AMPH to the brain would be sufficient to promote weight loss independently of behavior. 87 
To test this hypothesis, we chemically modified AMPH by PEGylation to increase its 88 
hydrodynamic radius and prevent its access to the brain (Pereira et al., 2017). PEGyAMPH does 89 
not cross the blood-brain barrier (BBB) yet retains the capacity to facilitate activation of 90 
sympathetic neurons and to increase peripheral NE availability in adipose tissues. This effect is 91 
mediated by the 2 adrenergic receptor (ADRB2), a known mediator of vasodilation and smooth 92 
muscle relaxation (Chruscinski et al., 1999; Ernande et al., 2016). PEGyAMPH does not block 93 
Slc6a2, but it binds ADRB2, with preservation of residue interactions, in the same binding site as 94 
epinephrine. PEGyAMPH is devoid of cardiovascular effects, which emerge if directly delivered 95 
to the brain,. PEGyAMPH has an anti-obesity size effect similar to that of AMPH, yet without 96 
suppression of food intake or increased locomotion. Its anti-obesity effect is attributable to 97 
elevated lipolysis, lipid utilization and energy expenditure (EE), increased thermogenesis coupled 98 
to higher heat-dissipation, which contribute as an sink energy whilst overriding caloric intake (Jung 99 
et al., 1979; Kasza et al., 2019; Schwartz et al., 1983; Wang, 1924; Warner et al., 2013).  100 
 101 
Results 102 
1. The anti-obesity effect of amphetamines requires an intact SNS. 103 
Despite being classified as sympathomimetic, to our knowledge, there are no literature reports on 104 
the ability of AMPH to directly activate sympathetic neurons. To bridge this literature gap, we 105 
utilized electrophysiology and calcium imaging to probe the effects of AMPH on the excitability of 106 
sympathetic neurons isolated from superior cervical ganglia (SCG). We began by recording firing 107 
patterns of wild-type sympathetic neurons isolated from C57BL/6 mice (Fig. 1. A-B) by whole-cell 108 
patch-clamp recordings under current-clamp mode. We observed that AMPH significantly 109 
increases the maximum firing frequency (Fig. 1. C, left panel), although no significant changes in 110 
resting membrane potential were detected (Fig. 1. C, right panel). These results demonstrate that 111 
AMPH treatment increases the intrinsic excitability of peripheral sympathetic neurons. In parallel, 112 
we also used dissociated cultures of TH-cre;CAG-LSL-GCaMP3 (GCaMP3+) reporter mice to 113 
performe calcium imaging. Local application of acetylcholine (ACh), a physiologic pre-ganglionic 114 
activator, leads to an intracellular [Ca2+] response in sympathetic neurons from GCaMP3+ mice in 115 
control experiments, which results in significantly higher increases upon treatment with AMPH 116 
(Fig. 1. D-F).  117 
Then, to investigate whether the increase of peripheral adrenergic signalling is required for the 118 
anti-obesity effect of AMPH, we subjected LSL-DTR (Control) and sympathectomized (Sup. Fig. 119 





(HFD) accompanied with AMPH treatment [120 µmol/kg of body-weight (BW) or control 121 
phosphate-buffered saline (PBS), daily intraperitoneal (IP) injections] for a total of 6 weeks, and 122 
assessed BW-gain over time. As expected, AMPH treatment protects Control mice from diet-123 
induced obesity (DIO; circular data points, Fig. 1. G and Sup. Fig. 1B). And, as we had previously 124 
reported (Pereira et al., 2017), Symp mice become extremely prone to DIO and gain twice as 125 
much weight as the Control group (white data points, Fig. 1. G). Surprisingly, both cohorts of 126 
Symp mice had very similar rate of BW-gain upon HFD exposure, regardless of treatment, which 127 
led to an approximately 40% increase after 6 weeks (triangular data points, Fig. 1. G and Sup. 128 
Fig. 1. B). This phenotype was independent of behavioural changes (Fig. 1. H-J), as upon  129 
treatment, both Control and Symp groups showed significant reduction in food intake (Fig. 1. H) 130 
and increase in locomotor activity (Fig. 1. I-J).  131 
Hence, we theorized that, underlying this phenotype, was the reduction in peripheral sympathetic 132 
output (NE levels), which would cause depression of adrenergic-stimulated lipolysis (Caron et al., 133 
2018; Pereira et al., 2017; Schwartz et al., 1983). To assess our hypothesis, we began by 134 
measuring the NE content in inguinal white adipose tissue (iWAT) of AMPH-treated mice and 135 
noted a significantly dampened response to AMPH treatment in Symp mice relative to Controls 136 
(Fig. 1. K). Additionally, we then analysed plasma lipid content to evaluate the levels of markers 137 
of lipolysis, which could explain the necessity of an intact SNS (Sup. Fig. 1. C). In fact, we found 138 
that in Symp mice, the behavioural effects of AMPH were not accompanied by an increase in SNS 139 
tone, nor by an elevation of lipolysis as seen in Control AMPH-treated mice (Fig. 1. K and Sup. 140 
Fig. 1. C).  141 
Combined, these results strongly support that the sympathomimetic activity of AMPH is required 142 
for its protection against weight gain. More importantly, the reduced food intake and increased 143 
locomotion observed upon AMPH treatment are ineffective at reducing the rate of BW-gain in the 144 






Figure 1. Amphetamine (AMPH) facilitates SNS activation which is required for the anti-obesity 147
effect, independently of hypophagia and hyperkinesia. A. Cultured superior cervical ganglia (SCG) 148
neurons transfected with Lenti-GFP and immuno-labelled for Tyrosine Hydroxylase (TH). B. Representative 149
traces of changes in membrane potential and action potential (AP) evoked under current-clamp mode by 150
injection 500ms current pulses (-25 to +275 pA in 25 pA increments) from an initial holding potential (Vh) 151
of -70 mV in Vehicle and AMPH treatment. C. Maximum AP firing frequency of Vehicle and AMPH-treated 152
neurons and Resting membrane potential of Vehicle and AMPH-treated neurons. D. Sequence of 153
representative pseudocolor images showing calcium levels ([Ca2+]) of one GCaMP3+ SCG neuron after 154





relative elevation from baseline 156 
0 = [(Fpost  Frest)/Frest] and are represented as pseudocolor scale. E. 157 
Representative ACh-induced [Ca2+] elevation response tracings. F. Amplitude of ACh-induced Ca2+ 158 
transients in Vehicle and AMPH-treated neurons (***p<0.001; n = 8; Statistics done using one-way ANOVA 159 
followed by Bonferroni correction). G. Change in Body 160 
Sympathectomized (Symp) mice during 6 weeks of High Fat Diet (HFD) exposure plus treatment with 161 
Phosphate-Buffered Saline (PBS) or Amphetamine (AMPH) (dose: 120 µmol/kg of BW, daily IP injections). 162 
H. Daily food intake during HFD exposure and respective treatment. I. Representative tracking of the 163 
Locomotor activity of both Control and Symp mice, measured 1 h post injection. J. Total distance travelled 164 
in 10min, 1h post injection. K. Norepinephrine (NE) content in inguinal white adipose tissue (iWAT), of 165 
Control and Symp mice after 6 weeks of HFD exposure and treatment with PBS or AMPH (dose: 120 166 
µmol/kg of BW, IP). (*p<0.05; **,##p<0.01; ***p<0.001;
 
****,####p<0.0001, n = 6-12. Statistics done using 167 
t-test, with Holm-Sidak correction method. *PBS versus AMPH; Control+PBS versus 168 
Symp+PBS, #Control+AMPH versus Symp+AMPH). Data presented as mean ± S.E.M. See also Figure S1. 169 
2. PEGylation of AMPH prevents its access to the brain and its behavioural effects. 170 
The BBB is generally impervious to large molecules, thus we resorted to chemical modification of 171 
AMPH by PEGylation (Pereira et al., 2017, see methods) to increase the hydrodynamic radius 172 
size, herein named PEGyAMPH (Fig. 2. A). To assess the success of this technique, we injected 173 
adult C57BL/6 mice with AMPH or PEGyAMPH (120µmol/kg of BW for both drugs or control PBS, 174 
IP) and collected brains 30 min and 2h afterwards. Brain extracts were then analysed by mass-175 
spectrometry to detect the presence of either molecule (Fig. 2. B). The 30 min  time-point was 176 
chosen for the analysis by the Fourier-transform ion cyclotron resonance (FT-ICR), because the 177 
half-life of AMPH in mice is reported to be 20 min (Riffee et al., 1978). Given its high resolution, 178 
one can identify the compound with errors lower than 1.5 ppm. From the replicate whole-brain 179 
samples, only in the group treated with AMPH was the drug detectable 30 min post-injection (Fig. 180 
2. B). Additionally, we also processed brain tissue by liquid chromatography with mass-181 
spectrometry LCMS detection (quantitative) and, possibly due to minimal penetration in areas 182 
where the BBB is not complete, we found a negligible quantity of PEGyAMPH relative to the levels 183 
observed of unmodified AMPH in the brain 30 min after IP administration, which then becomes 184 
undetectable 2h post-injection (Fig. 2. C). To confirm the brain mass-spectrometry analysis and 185 
consolidate our in vivo results, we also probed behavioural alterations in mice after IP 186 
administration of both drugs (Fig. 2. D-F). According to our previous results, AMPH treatment 187 
consistently supresses food intake (Fig. 2. D) and increases locomotor activity in mice (Fig 2. E 188 
and F). Importantly, we did not observe any changes in feeding behavior (Fig. 2. C) nor 189 
locomotion (Fig. 2. D and E) in PEGyAMPH-injected mice relative to those of the control PBS-190 
treated animals.  191 







Figure 2. PEGylated Amphetamine (PEGyAMPH) does not enter the brain and does not induce 195
hypophagia nor hyperkinesia. A. 196
PEGyAMPH. B. Representative Fourier-transform ion cyclotron resonance (FT-ICR) mass spectra of brain 197
extracts from C57BL/6 mice 30 min post-injection with PBS, AMPH or PEGyAMPH (dose: 120 µmol/kg of 198
BW for both drugs, IP). C. Brain levels of AMPH and PEGyAMPH after IP injection. D. 24h food intake post-199
injection with PBS, AMPH or PEGyAMPH (normal diet) E. Total distance travelled in 15min F. 200
Representative tracking of locomotor activity, measured 1 h post-injection. (*,#p<0.05;
 
****,####p<0.0001, n 201
= 4-10. t-test, with Holm-Sidak correction method*PBS versus 202
PEGyAMPH; #PBS versus AMPH.) Data presented as mean ± S.E.M. See also Figure S2. 203
3. PEGyAMPH facilitates SNS activation, via 2-adrenoceptor (ADRB2) signaling. 204
Next t  biologic activity, we treated SCG neurons with either AMPH or 205
PEGyAMPH and recorded the firing patterns, using whole-cell patch-clamp recordings under 206
current-clamp mode (Fig. 3. A-B and Sup. Fig. 3. A-C). The maximum firing frequency of 207
PEGyAMPH-treated neurons significantly increased relative to the control (Fig. 3. B), like AMPH, 208
with no significant changes in resting membrane potential  (Sup. Fig. 3. A). There was also a 209
significant increase in action potential (AP) firing threshold only detected between Vehicle and 210
PEGyAMPH-treated neurons (Sup. Fig. 3. B) and Sup. Fig. 211





the intrinsic excitability of sympathetic neurons. Additionally, we also assessed the effects of 213 
PEGyAMPH on free intracellular [Ca2+] levels of sympathetic neurons isolated from GCaMP3+ 214 
mice. There was a significant increase of ACh-induced calcium responses ( F/F0) after incubation 215 
with PEGyAMPH, relative to control values, similar to that observed in AMPH-treated sympathetic 216 
neurons (Fig. 3. C-E). To further confirm whether PEGyAMPH, like AMPH, had the capacity to 217 
elevate peripheral sympathetic tone, we conducted a dose response curve probing the NE content 218 
in iWAT and the livers of adult C57BL/6 male mice (Fig. 3. E). As expected, we found that 219 
PEGyAMPH increases NE content in metabolic tissues in a dose-dependent manner (Fig. 3. E).  220 
Moreover, to try to explain the biologic effect of PEGyAMPH, we also probed the effects of 221 
PEGylation . Pharmacokinetic analysis of both drugs 222 
revealed that PEGyAMPH has shorter circulating half-life compared to that AMPH (Sup. Fig. 2. 223 
A, 0.2 h vs 0.36 h, respectively), while it also appears to be more quickly metabolized in the liver 224 
(Sup. Fig. 2. B). As expect, the PEGylation greatly reduced excretion by the urine 225 
(Sup. Fig. 2. C) (Harris and Chess, 2003). To explore the functional properties of PEGyAMPH, 226 
we began by assessing its capacity to bind to the NE transporter (Slc6a2) in vitro, as this is 227 
reported to be a major target of AMPH (Heal et al., 2013). Of note, we observed a marked 228 
difference in capacity for binding Slc6a2; as AMPH displaces ~80% of the radioligand at 50 µM, 229 
while its PEGylated counterpart shows no activity at the same concentration (Sup. Fig. 2. D). This 230 
pharmacology differs from that of its unmodified counterpart.  231 
As such, we next evaluated the effect of replacing the NH3+ by an amide group in potential 232 
interactions of PEGyAMPH with adrenoceptors that have available X-ray structures. For this, we 233 
started by conducting docking calculations for both AMPH and PEGyAMPH with either the 1-234 
adrenoceptor (ADRB1) or the 2-adrenoceptor (ADRB2) (Sup. Fig. 3. D and Fig. 3. F, 235 
respectively). The X-ray structure reported for these receptors in complex with epinephrine (pdb 236 
ID: 6H7J and 4LDO, respectively) (Ring et al., 2013) was used as a 3D model of the protein. Of 237 
note, we found that both compounds occupy the same binding site as epinephrine. And these 238 
rigid-docking structures were also minimized in explicit solvent and ions using AMBER and GAFF 239 
force fields (Maier et al., 2015; Wang et al., 2004). According to our calculations, we found that 240 
the NH3+ group of AMPH is engaged in a hydrogen bond with the side chain of Asp256 of the 241 
ADRB2 (Fig. 3. F, left panel, see Methods for details). In addition, the methyl group of the drug is 242 
involved in a with Phe336 of this receptor, and its aromatic ring establishes 243 
hydrophobic contacts with several residues of ADRB2. Importantly, the complex between 244 
PEGyAMPH and ADRB2 is also stabilized by several hydrogen bonds. In particular, a prevalent 245 
hydrogen bond between the NH group of PEGyAMPH is formed with the side chain of Asp256 of 246 
the receptor, and an additional one involves the carbonyl group of this PEGylated compound and 247 
Tyr423 of ADBR2. Furthermore, the PEG chain of the drug is involved in two other hydrogen 248 






Figure 3. PEGyAMPH facilitates SNS activation, via 2-adrenoceptor (ADRB2) signaling. A. 251
Representative traces of changes in membrane potential and action potential (AP) evoked under current-252
clamp mode by injection 500-ms current pulses (-25 to +275 pA in 25 pA increments) from an initial holding 253
potential (Vh) of -70 mV in Vehicle, AMPH and PEGyAMPH treatment. B. Maximum AP firing frequency of 254
Vehicle, AMPH and PEGyAMPH-treated neurons. C. Sequence of representative pseudocolor images 255
showing [Ca2+]i changes of one GCaMP3+ superior cervical ganglia neuron after stimulation with 10 µM 256
ACh for 40 s (arrow). In each frame, the timing after the onset of ACh application is indicated. Changes in 257
fluorescence ( F) were measured as relative elevation from baseline fluorescence and expressed as F/F0 258





elevation response tracings in Vehicle, AMPH and PEGyAMPH-treated neurons (left), and Amplitude of 260 
ACh-induced Ca2+ transients in Vehicle-treated neurons and after pharmacological treatment with AMPH 261 
and PEGyAMPH (right). (***p<0.001; n = 3-4; Statistics done using one-way ANOVA followed by Bonferroni 262 
correction). E. Increase in NE content of iWAT (left) and liver (right) of C57BL/6 mice 3h post-treatment 263 
with PEGyAMPH (doses: 60, 120 or 240 µmol/kg of BW,IP injections) without access to food, relative to 264 
baseline levels. F. 3D structure of 2-adrenoceptor in complex with AMPH and PEGyAMP. Left: Minimized 265 
structure calculated by Molecular Mechanics (MM) for ADRB2/AMPH complex, showing the most relevant 266 
interactions between AMP and the receptor. Right: Minimized structure calculated by MM for 267 
ADRB2/PEGyAMPH complex, showing the most relevant interactions ligand-receptor. ADBR2 is 268 
represented as white ribbons and the carbon atoms of the residues of this receptor that are interacting with 269 
the ligands are in yellow. The carbon atoms of the ligands are in green. G. Representative ACh-induced 270 
[Ca2+]i elevation response (left), and amplitude of ACh-induced Ca2+ transients in Vehicle-treated neurons 271 
and after pharmacological treatment with PEGyAMPH, in the absence and presence of the ADRB2 272 
antagonist butoxamine (BUT) (right). (***p<0.001; n = 3-4; Statistics done using one-way ANOVA followed 273 
by Bonferroni correction). (*,#p<0.05;
 
***p<0.001; ****p<0.0001, n = 8-12. Statistics done using unpaired 274 
t-test, with Holm-Sidak correction method. *PBS versus PEGyAMPH; #PEGyAMPH versus 275 
PEGyAMPH+BUT) Data presented as mean ± S.E.M. See also Figure S3. 276 
As reported by our calculations, the replacement of the NH3+ by an amide group does not 277 
significantly disturb the interactions with the adrenoceptors tested (Fig. 3. F and Sup. Fig. 3. D, 278 
ADRB1 and ADRB2, respectively). This aligns with the ability of PEGyAMPH to modulate 279 
sympathetic tone to metabolic tissues (Fig. 3 E and Sup. Fig. 3 E-F). Moreover, to experimentally 280 
probe the effect of specific engagement of ADRB2 by PEGyAMPH on its sympathofacilitator 281 
properties, we performed ACh-induced [Ca2+] elevation response imaging assays and found that 282 
butoxamine (BUT - a selective ADRB2 antagonist; Gabanyi et al., 2016) 283 
capacity to amplify neuronal activation by ACh (Fig. 3. G).  284 
Hence, PEGylation of AMPH changed its pharmacology, but it did not reduce the 285 
sympathofacilitator activity, which seems to rely on ADRB2 engagement. 286 
 287 
4. PEGyAMPH does not affect cardiovascular function in mice, unless it is centrally 288 
delivered.  289 
The anti-obesity effects of AMPH-like compounds are proposed to be driven by its modulation of 290 
behaviour, yet these drugs are coined sympathomimetics (Heal et al., 2013) in reference to their 291 
well-known cardiovascular side effects, such as tachycardia and hypertension. Surprisingly, we 292 
found that the respiratory and cardiovascular effects characteristic of AMPH were absent when 293 
PEGyAMPH is administered intraperitoneally (Fig. 4. A-C, and Sup. Fig. 4. A). In fact, it is insofar 294 
unclear whether the cardiac sympathomimetic effects of AMPHs originate peripherally, by direct 295 
activation of the SNS, or centrally, by brain-dependent action (Heal et al., 2013). Surprisingly, 296 
although sympathomimetic drugs are classically described to exert excitatory effects on the 297 
cardiovascular system, our peripherally acting drug did not cause elevation of blood pressure 298 
(Fig. 4. A and B) or heart rate (Fig. 4. C and Sup. Fig. 4. A, right panel). Concomitantly, we also 299 
detected less accumulation of the drug (Sup. Fig. 4. B) and of NE in the hearts (Sup. Fig. 4. C) 300 






Figure 4. PEGyAMPH, 303 
unlike AMPH, does not 304 
affect cardiovascular 305 
function, unless delivered 306 
centrally.  307 
A. Mean Blood Pressure 308 
(MBP) B. Systolic Blood 309 
Pressure (SBP) and Diastolic 310 
Blood Pressure (DBP) C. 311 
Heart rate of C57BL/6 mice, 312 
recorded 30-45 min post-313 
injection with PBS, AMPH or 314 
PEGyAMPH (dose: 120 315 
µmol/kg of BW for both drugs, 316 
IP) using a non-invasive 317 
Volume Pressure Recording 318 
(VPR) tail-cuff system (D-G) 319 
Measurements taken post-320 
ICV injection of PBS, AMPH 321 
or PEGyAMPH (60nmol, 322 
bolus, per animal) D. Change 323 
in heart rate recorded 15 min 324 
post-injection under 325 
anesthesia (2% isoflurane) 326 
using a CollarClip Sensor 327 
(CC-Sensor) for pulse-328 
oximetry. E. 24h food intake of 329 
ICV-injected mice F. Total 330 
distance travelled in 10 min  331 
G. Representative tracking of 332 
locomotor activity, recorded 333 




***,###p<0.001; ####, p<0.0001, n = 8-12. t-test, with Holm-Sidak 336
correction method. *PBS versus PEGyAMPH; #PBS versus AMPH, PEGyAMPH versus AMPH) Data 337
presented as mean ± S.E.M. See also Figure S4. 338
A central action seems to be a viable possibility, as the brain robustly controls heart rate and 339
vascular capacitance in response to multiple internal and external stimuli (Malpas, 2010). To test 340
this hypothesis, we probed the effect of central administration of both drugs via 341
intracerebroventricular (ICV) injection (bolus of 60nmol, for PEGyAMPH or AMPH). As expected, 342
PEGyAMPH had equivalent anorexic effect (Fig. 4. E) and capacity to induce hyperkinesia (Fig. 343
4. F-G) as AMPH. Importantly, we confirmed that ICV injections were sufficient to induce 344
excitatory effects on the cardiorespiratory system (Fig. 4. D and Sup. Fig. 4. D).  345
Combined, our results suggest that the well-described cardiovascular stress induced by 346





5. PEGyAMPH protects mice from obesity by elevating EE, without affecting feeding 348 
behaviour or locomotor activity. 349 
Recent evidence from our group and others (Camell et al., 2017; Pereira et al., 2017; Pirzgalska 350 
et al., 2017) clearly demonstrates that peripheral NE regulates adiposity levels independent of 351 
food intake or exercise. As such, we hypothesized that PEGyAMPH treatment would be sufficient 352 
to promote long term anti-obesity results regardless of excess caloric intake. To investigate this, 353 
we exposed adult C57BL/6 mice to HFD and treatment with either AMPH or PEGyAMPH (120 354 
µmol/kg of BW for both drugs or control PBS, daily IP injections) for a total of 10 weeks and 355 
subsequently assessed their rate of weight gain and metabolic alterations. As demonstrated 356 
before, AMPH therapy protects wild type mice from DIO after 10 weeks of HFD (Fig. 5. A and B, 357 
red data points). sympathofacilitator activity is sufficient to protect BW 358 
in dose-dependent manner (Sup. Fig. 3. G). Notably, when administrated in equimolar dose, 359 
treatment with PEGyAMPH showed similar size effect on promoting leanness under HFD 360 
exposure to that of its unmodified counterpart. (Fig. 5. A and B, blue data points). Both therapies 361 
improved peripheral insulin sensitivity, as blood glucose levels did not differ between all the HFD-362 
exposed groups (Sup. Fig. 5. A), but the circulating plasma insulin levels were significantly lower 363 
in the treated groups compared to those of PBS controls (Sup. Fig. 5. B). Given that the SNS is 364 
reported to not only control insulin sensitivity but also insulin secretion (Morton et al., 2017, 365 
Nonogaki, 2000; Ruud et al., 2017), we quantified the NE content in the pancreas of C57BL/6 366 
mice after 10 weeks of HFD exposure and respective treatment, and observed that only AMPH 367 
increased SNS output to this tissue (Sup. Fig. 5. C). Thus, PEGyAMPH treatment prevents the 368 
development of hyperinsulinemia and improves glucose homeostasis by increasing peripheral 369 
insulin sensitivity without suppressing its secretion. Of note, analysis of liver gene expression 370 
revealed that both treated groups had a two-fold elevation of phosphoenolpyruvate carboxykinase 371 
(PEPCK) gene expression (Sup. Fig. 5. D), which is a major integrator of energy metabolism 372 
(Burgess et al., 2007; Petersen et al., 2017; She et al., 2000). The higher insulin sensitivity found 373 
in treated animals during the fed-state was not associated with significant differences in glucose 374 
levels during an IP glucose tolerance test (GTT - Sup. Fig. 5. E and G). Yet, the PEGyAMPH-375 
treated group revealed a trend towards higher peripheral glucose uptake during an insulin 376 
tolerance test (ITT - Sup. Fig. 5. F and H). Combined, these results indicate that long-term 377 
treatment with PEGyAMPH protects mice from DIO and improves glucose homeostasis during 378 
HFD exposure. As expected, we found that PEGyAMPH-treated mice did not decrease their food 379 
intake (Fig. 5. C) nor increase locomotor activity (Fig. 5. D and Sup. Fig. 5. H) upon chronic 380 
treatment. Nonetheless, indirect calorimetry revealed that, under HFD feeding, this group had 381 
slightly higher EE compared to the PBS controls (Fig. 5. E. and Sup. Fig. 5. G) despite having 382 
similar behaviour. 383 






Figure 5. PEGyAMPH protects mice from diet-induced obesity (DIO) and increases energy 386
expenditure (EE) without affecting food intake. A. Body weight and B. change in body weight 387
C57BL/6 mice during 10 weeks of HFD exposure with PBS, AMPH or PEGyAMPH treatment (dose: 120 388
µmol/kg of BW for both drugs, daily IP injections) C. Weekly food intake of HFD D. Quantification of daily 389
locomotor activity in beam break counts per day E. Total 48h normalized EE E. Daily fecal output (left) and 390
fecal TGs content (right) G. Plasma TGs levels measured 2h post-injection without access to food H. Body 391
weight and I.  of diet induced obese (DIO) mice during 3 weeks of treatment with PBS, AMPH or 392
PEGyAMPH (dose: 120 µmol/kg of BW for both drugs, daily IP injections). (*,#, p<0.05; **,##, p<0.01;
 
393
###, p<0.001; ****,####p<0.0001, n = 8-15. t-test, with Holm-Sidak 394
correction method. *PBS versus PEGyAMPH; #PBS versus AMPH; PEGyAMPH versus AMPH.) Data 395





Moreover, we also analysed the effects of PEGyAMPH treatment on dietary lipid absorption and 397 
found that PEGyAMPH did not alter the total 24h fecal output nor its lipid content (Fig. 5. F). 398 
Concomitantly, plasma TGs levels of PEGyAMPH-treated mice were also unchanged relative to 399 
controls (Fig. 5. G). Hence, we can conclude that PEGyAMPH promotes leanness by overriding 400 
caloric intake during HFD exposure. Finally, to test the efficacy of the treatments in inducing 401 
weight loss in already-obese animals, we also treated  C57BL/6 mice previously exposed for 402 
minimum of 3 months to HFD with either AMPH or PEGyAMPH (120 µmol/kg of BW, IP), and 403 
found that both drugs caused significant weight loss (>10%) after just 3 weeks of daily injections 404 
(Fig. 5. H-I). Altogether, our results suggest that treatment with PEGyAMPH during HFD exposure 405 
overrides food intake by increasing EE and adrenergic-stimulated metabolic pathways. 406 
6. PEGyAMPH protects from obesity by elevating lipolysis and lipid utilization. 407 
Given that  during DIO are dose dependent, as are its 408 
sympathofacillitor properies (Sup. Fig. 3. G and Fig. 3. E, respectively), to begin dissecting the 409 
anti-obesity mechanism we started by analysing the sympathetic output to adipose tissue of 410 
C57BL/6 mice after 10 weeks of HFD exposure and chronic treatment. Surprisingly, the 411 
PEGyAMPH-treated group exhibited a significantly greater increase in NE content in iWAT 412 
compared not only to the control group but also with that of the AMPH-treated animals (Fig. 6. 413 
A). This was also associated with the presence of much higher levels of lipolytic markers in 414 
circulation, namely free fatty acids (FFAs  Fig. 6. B) and glycerol (Fig. 6. C), highlighting the 415 
potential of PEGyAMPH for chronic treatment. Nonetheless, we observed a marked reduction in 416 
iWAT adipocyte size (Fig. 6. D and E) in both treated groups relative to the same depot of PBS-417 
treated animals after HFD exposure.  418 
Next, we probed changes in gene expression of metabolic tissues induced by both treatments. 419 
PEGyAMPH induced an almost three-fold increase 3 adrenergic receptor (ADRB3) expression 420 
in WAT, but not in BAT, after 10 weeks of HFD exposure (Fig. 6. F and G). We also evaluated 421 
the levels of other lipolysis-associated genes after treatment and observed that PEGyAMPH 422 
induced a two-fold upregulation of hormone-sensitive lipase (HSL) in both WAT and BAT, 423 
whereas adipose triglyceride lipase (AtgL) was only elevated in WAT (Fig. 6. F and G). Combined 424 
with the upregulation of adipose lipolysis, SNS output was also elevated in liver (Sup. Fig. 6. A) 425 
and skeletal muscle (Sup. Fig. 6. D) after treatment with PEGyAMPH during HFD feeding, which 426 
suggests higher metabolic performance, i.e. higher utilization of lipid stores (Geerling et al., 2014; 427 
Nonogaki, 2000). In line with this hypothesis, we found decreased TG content (Sup. Fig. 6. B), 428 
accompanied by an increase of glycogen (Sup. Fig. 6. C) in the livers of PEGyAMPH-treated 429 
mice. By performing Oil-Red O (ORO) staining and quantification (Fig. 6. H and I), we confirmed 430 
a marked reduction in hepatic steatosis. In the skeletal muscle of these animals, PEGyAMPH 431 
caused a reduction in the levels of TGs (Sup. Fig. 6. E) while preserving glycogen stores (Sup. 432 
Fig. 6. F). Quantification of gene expression in the liver and muscle also revealed alteration of 433 
lipid metabolism in these tissues (Sup. Fig. 6. G and H, respectively).  434 






Figure 6. PEGyAMPH elevates adipose tissue lipolysis and peripheral lipid utilization during DIO. A. 437
NE content in iWAT of C57BL/6 mice after 10 weeks of HFD exposure and treatment with PBS, AMPH or 438
PEGyAMPH (dose: 120 µmol/kg of BW for both drugs, daily IP injections) B and C. Plasma levels of FFAs 439
(B) and glycerol (C) of C57BL/6 mice 2 h post-injection with PBS, AMPH or PEGyAMPH without access to 440
food, measured 4-5 weeks after the start of HFD exposure and respective treatment (D-I) Histology and 441
gene expression analysis of metabolic tissues from C57BL/6 mice after the conclusion of 10 weeks of HFD 442
exposure and treatment with PBS, AMPH or PEGyAMPH. D. Representative histologic slices of iWAT 443
stained with haematoxylin and eosin (H&E) and E. Quantification of iWAT adipocyte size F and G. Lipolytic 444
gene expression levels of 3 adrenergic receptor (ADRB3), Adipose triglyceride lipase (AtgL) and Hormone-445
sensitive lipase (HSL) in iWAT (F) and in BAT (G) determined by qRT-PCR relative to housekeeping gene 446
Arbp0 H. Representative histologic slices of liver with Oil-Red O (ORO) staining I. ORO-stained liver area 447
normalized to the total area. (*,#, p<0.05; **p<0.01;
 
***,###, p<0.001; ****,####p<0.0001, n = 5-12. Statistics 448
t-test, with Holm-Sidak correction. *PBS versus PEGyAMPH; #PBS versus 449






elevation of peripheral lipid breakdown and utilization, highlighting the SNS as a major regulator 452 
of adiposity during excessive caloric intake. 453 
7. PEGyAMPH protects from obesity by elevating thermogenesis and heat dissipation 454 
via ADR2B. 455 
Activation of thermogenesis, which is also controlled by the SNS and can act as an energy sink, 456 
is proposed to promote resistance to obesity (Rothwell and Stock, 1979). Nonetheless, the rapid 457 
increase in EE observed upon AMPH administration could be a result of increased locomotor 458 
activity, and thus the contribution of its thermogenic activity to the elevation of basal metabolic 459 
rate and BW management is still debated (Arch and Trayhurn, 2013). To probe the thermogenic 460 
effect of each drug, we began by using thermographic photography to analyse BAT temperature 461 
in HFD-fed mice. After PEGyAMPH treatment, there was an elevation in BAT temperature similar 462 
to that evoked by AMPH (2h post-injection - Fig. 7. A and B). Accordingly, we also found that 463 
after 10 weeks of HFD and drug treatment, both amphetamines caused a fifteen-fold upregulation 464 
of the primary BAT thermogenic marker, uncoupling protein 1 (UCP1), and increased all other 465 
thermogenic genes probed (Fig. 7. C). This was accompanied by an eight-fold increase in the 466 
levels of expression of glucose-transporter-type-4 isoform (GLUT4) in BAT of mice treated with 467 
both drugs (Sup. Fig. 7. A), which indicates higher glucose uptake by this organ. GLUT4 has 468 
been reported to be a marker for higher thermogenic activity (Lee et al., 2016) and could account 469 
for the increased insulin sensitivity compared to PBS-treated controls (Sup. Fig. 5. B). Although 470 
UCP1 levels were not changed in iWAT, the other thermogenic genes quantified were upregulated 471 
relative to the levels observed in the control group (Sup. Fig. 7. A), and others have reported 472 
thermogenesis with invariant UCP1 (Granneman et al., 2003; Ikeda et al., 2017, 2018). The 473 
combination of these results points to a general trend for elevated thermogenesis after 474 
PEGyAMPH treatment, which underlies its protection against DIO, overriding caloric intake.  475 
Surprisingly, we  also detected that only AMPH caused transient hyperthermia after its 476 
administration (Borbély et al., 1974), while PEGyAMPH-treated mice remain normothermic, i.e. 477 
they had core body temperature identical to that of the control group (Fig. 7. D). This suggests 478 
that, although both drugs act as sympathomimetics, they might actually have different actions on 479 
peripheral heat dissipation (Blessing et al., 2016). Hence, to assess vasoconstriction at the 480 
extremities, we probed the local temperature at the tail base by thermography (Fischer et al., 481 
2016, Warner et al., 2013). As such, we found that, despite the similar core body temperature, 482 
PEGyAMPH-injected mice had significantly warmer tails relative to those of the PBS controls (Fig. 483 
7. E and F). This indicates that, unlike AMPH, PEGyAMPH  sympathomimetic activity increases 484 
thermogenesis without causing vasoconstriction, suggesting that heat dissipation could be a 485 
relevant component of body weight regulation (Jéquier et al., 1974; Kasza et al., 2019; Warner et 486 
al., 2013). Given that PEGyAMPH-treated mice seem to rely on activation of thermogenesis to 487 
remain lean, we also probed the effect of the drug during HFD exposure under thermoneutral 488 
housing conditions. As expected, PEGyAMPH weight-reducing potency is decreased in this 489 
environmental setting, yet some level of protection against DIO does remain (Fig. 7. G and Sup. 490 






Figure 7. PEGyAMPH increases thermogenesis, heat dissipation and protects against obesity via 493
ADR2B. All thermal measurements were performed 2 h post-injection with PBS, AMPH or PEGyAMPH 494
(dose: 120 µmol/kg of BW for both drugs, IP. A. Representative infrared thermography of the BAT area 495
temperature B. Quantification of BAT skin area temperature measured with thermography C. BAT mRNA 496
levels of thermogenic genes   determined by qRT-PCR relative to housekeeping gene Arbp0, after 10 weeks 497
of HFD exposure and treatment with PBS, AMPH or PEGyAMPH D. Core body temperature measured with 498
rectal probe E. Representative infrared thermography of tail temperatures. F. Quantification of tail 499
temperature measured 0,5 cm from the  tail base with thermography G. C57BL/6 mice mice 500
exposed to HFD and treatment with PBS, AMPH or PEGyAMPH (dose: 120 µmol/kg of BW for both drugs, 501
daily IP injections) under thermoneutral housing conditions H.  and I. Daily food intake of C57BL/6 502
mice exposed to HFD and treatment with PBS or PEGyAMPH (dose: 120 µmol/kg of BW, daily IP 503
injections), in combination with BUT (dose: 16 µmol/kg/day, via osmotic pumps) (*,#, p<0.05; **,##p<0.01;
 
504
***,###p<0.001; ****,####, p<0.0001, n = 8-12. t-test, with Holm-505
Sidak correction. *PBS versus PEGyAMPH; #PBS versus AMPH; PEGyAMPH versus AMPH.) Data 506





Hence, treatment with PEGyAMPH protects mice against obesity by elevating thermogenesis 508 
coupled to heat dissipation, the latter of which relies on vasodilation/smooth muscle relaxation 509 
and is well known to be driven by ADRB2 (Chruscinski et al., 1999; Ernande et al., 2016). 510 
Consistently, we discovered that the anti-obesity effect of PEGyAMPH is completely abrogated 511 
by a selective ADRB2 antagonist (butoxamine, delivered via osmotic pumps - Fig. 7. H-I), further 512 
validating that this pathway is important  513 
Altogether, these results confirm that PEGyAMPH is a peripheral sympathofacilitator anti-obesity 514 
drug that activates a whole-body energy sink by coupling thermogenesis to heat dissipation 515 
without inducing behavioural changes nor cardiotoxicity. 516 
 517 
Discussion  518 
The primary mechanism of action that underlies the anti-obesity effect of AMPH-based drugs, 519 
such as FDA-approved phentermine, is based on an effect in the brain that conveys pronounced 520 
behavioural effects: anorexia and hyperkinesia. Phentermine is a centrally acting anorexigenic 521 
drug that was developed as a less addictive option to other AMPH forms. However, studies in 522 
rodents have suggested that the anti-obesity effects of AMPHs and other anorexigenic drugs are 523 
partly, or even entirely, a result of non-behavioural factors (Arch, 1981; Herling et al., 2008). 524 
Although anorexia unquestionably reduces BW, our results indicate that this effect depends on 525 
an intact sympathetic axis (Pereira et al., 2017). As ADRB3 was described to be the main receptor 526 
mediating adrenergic-stimulated lipolysis in rodent adipocytes (Bloom et al., 1992; Guerra et al., 527 
1998; Himms-Hagen et al., 1994; Susulic et al., 1995; Xiao et al., 2015), direct sympathomimetic 528 
agents, such as the ADRB3 agonist CL-316,243, were once regarded as potential anti-obesity 529 
therapies. However, as human lipolysis is mainly mediated by the other -adrenoreceptors, 530 
ADRB3 agonists failed as anti-obesity therapies, and they are instead indicated for urogenital 531 
conditions (Arch, 2011; Lafontan and Berlan, 1993; Ursino et al., 2009). Direct thermogenic drugs 532 
such as compound 2,4-dinitrophenol, a mitochondrial uncoupler, were very effective anti-obesity 533 
treatments through converting energy to heat, but they also cause substantial side effects, 534 
including life-threatening hyperthermia (Harper et al., 2001). The historical failure of post-synaptic 535 
targeting in adipose tissue is suggestive of an orchestrated multi-pathway and multi-organ 536 
programme that is pre-synaptically controlled by the SNS (Bartness et al., 2014; Mahú and 537 
Domingos, 2017; Zeng et al., 2015). Thus, we reasoned that a pre-synaptic facilitation of 538 
sympathetic output would have a more potent effect, as SNS circuits would simultaneously 539 
activate multiple pathways, not only in WAT, but also in BAT and other metabolically relevant 540 
organs.  541 
Indirect sympathomimetics, such as FDA-approved phentermine, demonstrated higher anti-542 
obesity efficacy relative to the direct class but have prohibitive cardio-excitatory effects. However, 543 
whether this side effect is mediated via the brain or periphery has never been experimentally 544 
tested. We herein address this by testing the first-in-class exclusively peripheral AMPH, which 545 
does not enter the brain and is devoid of cardiovascular side effects. We reasoned that 546 
PEGylation of AMPH would render the molecule sufficiently big and impermeable to the brain. 547 





(Veronese, 2001), but whether it would successfully prevent brain access was uncertain, as 549 
variable BBB permeability has been reported in the literature depending on the molecule to be 550 
chemically modified (Pereira et al., 2017; Veronese, 2001). By using mass spectrometry of brain 551 
extracts, we document that PEGyAMPH does not reach the brain, yet it retains its ability to 552 
facilitate the activation of sympathetic neurons in vitro and in vivo, thus constituting the first in 553 
class of a peripheral sympathofacilitator with an anti-obesity action. PEGyAMPH reduces obesity 554 
with a size effect comparable to that of AMPH, yet with a distinct mechanism in that it spares 555 
effects relating to brain action, such as anorexia, hyperkinesia, and tremor. It also spares 556 
tachycardia and hypertension, and this could not be expected unless experimentally 557 
demonstrated, as we have done here. This distinction could be related to different molecular 558 
targets: unlike AMPH, PEGyAMPH does not bind Slc6a2, likely due to the loss of the amine group. 559 
Importantly, this group is not essential for interaction with the ADRB2, which we demonstrate to 560 
mediate the sympathofacilitatory and anti-obesity effect of PEGyAMPH. Elevation of SNS tone 561 
both to WAT and BAT activates lipolysis and thermogenesis (Bartness et al., 2014; Contreras et 562 
al., 2017; Hausberg et al., 2002; Mahú and Domingos, 2017; Zeng et al., 2015). Simultaneously, 563 
ADRB2 agonism is well known to lead to smooth muscle relaxation and vasodilation, which bode 564 
well to mediate the cardioprotective actions of PEGyAMPH, as well as its effect on thermal 565 
dissipation. Consistently, others have shown that the ADRB2-selective agonist salbutamol, 566 
increases BAT vasodilation and tissue perfusion, activating thermogenesis without directly 567 
targeting brown adipocytes (Ernande et al., 2016). The authors of this report did not assess 568 
changes in peripheral vasculature, and we did not probe BAT perfusion, but it is quite possible 569 
that PEGyAMPH might also increase blood flow to this tissue, further boosting thermogenesis. 570 
Moreover, although the relationship between peripheral vascular tone and cardiac function is 571 
undebatable (Delong and Sharma, 2019), the effect of blood flow on heat dissipation and its 572 
connection to metabolic regulation has only recently began to be appreciated as an important 573 
component of adiposity control. In fact, compensatory thermoregulation seems to drive 574 
hypermetabolic phenotypes in animals with genetic manipulations that facilitate heat dissipation 575 
(Kasza et al., 2019; Warner and Mittag, 2014; Warner et al., 2013).  576 
Our results put forward the idea that coupling increased thermogenesis with peripheral heat 577 
dissipation, constitutes a sink for EE without causing hyperthermia and that AMPH-like 578 
compounds, such as FDA-approved phentermine or ADRB2 agonists, which are not indicated for 579 
long-term systemic use due to serious side effects, could be reformulated to become brain 580 
impermeable.  Overall, our results are a proof-of-principle that peripheral sympathofacilitators 581 
could be a new generation of anti-obesity compounds that circumvent difficulties caused by BBB 582 
permeability and avoid brain-related side effects, including those relating to cardiovascular 583 
function.  584 
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Methods 633 
PEGylation of Amphetamine (PEGyAMPH synthesis). Inspired by Yang et al., 2009. Briefly, in 634 
a round-bottom flask (R)-1-phenylprop-2-ylamine hydrochloride salt (103 mg, 0.6 mmol, 2 equiv., 635 
Asiba Pharmatec.) was placed under inert atmosphere. A solution of methyl-PEG-NHS-ester 636 
reagent (1.1 mL, 100 mg, 0.39 mmol, 1 equiv., Thermo Scientific) in DMSO was then added, 637 
followed by the addition of diisopropylethylamine (DIPEA, 105 µL, 0.6 mmol, 2 eq, Sigma-Aldrich). 638 
The reaction was stirred at room temperature for 46 h, after which a multiple extraction with 639 
water/ethyl acetate was performed to remove the product from DMSO. Then preparative 640 
chromatography (5% EtOAc in MeOH, v/v) was performed to isolate compound PEGyAMPH in 641 
98% yield (0.1 g). Characterization: 1H NMR (300 MHz, CDCl3)  7.25  7.11 (m, 5H), 6.53  6.26 642 
(m, 1H), 4.19 (p, J = 6.8 Hz, 1H), 3.63  3.47 (m, 14H), 3.32 (s, 3H), 2.79 (dd, J = 13.5, 6.1 Hz, 643 
1H), 2.65 (dd, J = 13.5, 7.1 Hz, 1H), 2.37 (t, J = 6.4 Hz, 2H), 1.06 (d, J = 6.6 Hz, 3H) ppm. 13C 644 
NMR (75 MHz, CDCl3)  170.92, 138.38, 129.55, 128.36, 126.40, 72.01, 70.70, 70.60, 70.46, 645 
70.34, 67.43, 59.11, 46.02, 42.60, 37.21 ppm. HRMS: [M+H]+calc = 354.22750; [M+H]+real = 646 
354.22783 (error 0.9 ppm). Scale-up of the reaction for chronic in vivo treatments was 647 
reproduced by Wuxi AppTec. 648 
Mice and housing conditions. Mice were housed at controlled temperature and humidity, under 649 
a 12 h light/dark cycle. Food and water were supplied ad libitum, unless mentioned otherwise. 650 
The animal experiments were performed in agreement with the International Law on Animal 651 
Experimentation and were approved by the IGC ethics committee and by the USC Ethical 652 
Committee (Project ID 15010/14/006). C57BL/6 mice were obtained from the Mice Production 653 
Facility at the IGC. TH-cre (Jax, #008601), CAG-LSL-GCaMP3 (Jax, #014538), LSL-DTR (Jax, 654 
#007900), mice were purchased from Jackson Laboratory, and bred to produce homozygous TH-655 
cre; CAG-LSL-GCaMP3 and TH-cre; LSL-DTR mice. LSL-DTR mice were used as controls for 656 
the sympathectomization studies.  657 
PEGyDT-mediated regional sympathectomy. For detailed characterization refer to Pereira et 658 
al. 2017. Briefly, 7-8 weeks old TH-cre; LSL-DTR male mice were used for genetic-659 
sympathectomy experiments and aged-matched LSL-DTR were used as controls. PEGylated 660 
Diphtheria Toxin (PEGyDT) was administered once a day for 8 consecutive days (25 ng/g of BW, 661 






High-fat diet challenge and chronic treatments. All mice used for DIO challenges and follow-664 
up metabolic analysis were males. When C57BL/6 mice reached 8 weeks of age, or 1 day after 665 
sympathectomy protocol was performed in both TH-cre; LSL-DTR and respective controls LSL-666 
DTR, normal diet was replaced with high fat diet (HFD, Ssniff, Spezialdiäten, Soest, Germany, 667 
D12492) concomitantly with treatment of either AMPH or PEGyAMPH (dose: 120 µmol/kg of BW 668 
for both drugs diluted in PBS, daily IP injections). Length of exposure to HFD and treatment is 669 
indicated in figure legends.   670 
Intracerebroventricular treatments. Intracerebroventricular (ICV) cannulae were stereotaxically 671 
implanted under a mix of inhaled isoflurane and oxygen, using the following coordinates 1.5 mm 672 
lateral to bregma, 0.6 mm posterior, 4.0 mm deep. Mice equipped with ICV cannulae were given 673 
7 days to recover before injections and measurements. A bolus ICV injection of AMPH or 674 
PEGyAMPH (60 nmol, diluted in 5 µL of PBS), or of PBS as control was acutely administrated for 675 
behavioural and cardiorespiratory measurements as described below. 676 
Non-invasive Cardiovascular Measurements. Blood Pressure and Heart Rate were measured 677 
from awake restrained animals using a Volume Pressure Recording (VPR) sensor and tail-cuff 678 
system (CODA, Kent Scientific Corporation). To prevent stress-related effects, mice were trained 679 
for a minimum of 3 days before measurements. At least 15 accurate measurements per animal 680 
were used for analysis of diastolic, mean and systolic pressure and at least 8 for analysis of the 681 
heart rate. Baseline was recorded just before injection, and the effect of the drugs was measured 682 
15-30 min post injection with PBS, AMPH or PEGyAMPH (dose: 120 µmol/kg of BW for both 683 
drugs, daily IP injections). 684 
Infrared pulse oximetry. The day before measurements the hair around the neck of each mouse 685 
was removed using Veet cream (Unilever). 24-48h post-depilation, the cardiopulmonary status of 686 
each mouse was analyzed by MouseOx Plus (Starr Life Sciences Corp) in accordance with 687 
manufacturer's instructions. Each mouse was very briefly anaesthetised using 5% isoflurane to 688 
facilitate placement of a CollarClip Sensor, and allowed to acclimatize to the anesthesia with 1-689 
2% isoflurane for 5 min. This time window was sufficient for animals to recover normal activities 690 
and physiological readings. Measurements were then recorded for 5-10 min at baseline and then 691 
for another 10-15min after injections (IP of PEGyAMPH and AMPH, dose: 120 µmol/kg of BW for 692 
both drugs; or ICV of PBS and AMPH, dose: 60nmol, bolus per animal). The time points described 693 
were used to collect representative, error-free data due to the motion artefact (DeMeulenaere, 694 
2007). 695 
Locomotion assays. After 3 weeks of HFD exposure and treatment, mice were acclimated to 696 
tracking cages for 1 week before starting the 72h locomotion measurements by using a high 697 
throughput tracking system (LabMaster, TSE Systems). Animals were also filmed for 20-30 min, 698 
with a ZEISS optics camera 1 h post injection inside their normal housing cage, for assessment 699 
of total distance travelled. Footage-records were filtered by using video editor Avidemux 700 
(Avidemux 2.7.1) and 10-15 min distance computations were quantified with the TrackMate 701 
tracking plugin from Fiji (Fiji; Wisconsin-Madinson). 702 
Calorimetry assays. Animals were analysed for Energy Expenditure (EE) using a calorimetric 703 
system (LabMaster; TSE Systems). Animals were placed in a temperature-controlled (24°C) box 704 





0.05% CO2 and 79.05% N2), the metabolic rate was measured for 2-3 days, and EE was recorded 706 
every 30 min. Animals were placed for adaptation for 1 week before starting the measurements. 707 
Normalized EE was calculated as described in Tschöp et al. (2012) and the distribution curves 708 
were obtained using the CalR Web-based tool (Mina et al., 2018). 709 
Glucose metabolism tests. For the intraperitoneal Glucose Tolerance Test (GTT), mice were 710 
injected with PBS, AMPH or PEGyAMPH and then fasted for 6 h, before being given 2 g 711 
glucose/kg of BW, IP. Blood was drawn from the tail vein and glucose levels were measured using 712 
a glucometer (Accu-Check System, Roche) at 0, 15, 30, 60, 90, and 120 min after glucose 713 
administration. For the Insulin Tolerance Test (ITT), mice were injected with PBS, AMPH or 714 
PEGyAMPH and then fasted for 2 h, before being given (IP) 0.9U/kg of BW, IP,  of recombinant 715 
human insulin (Sigma), blood glucose levels were measured at 0, 15, 30, 60, 90, 120, 150 and 716 
180 min after insulin administration. 717 
Thermoregulation studies. All measurements were done in ad libitum fed mice 2 h post-718 
injections with PBS, AMPH or PEGyAMPH. Rectal temperature was measured with an electronic 719 
thermometer (Precision). BAT and Tail thermographic pictures were taken with a Compact-720 
Infrared-Thermal-Imaging-Camera (FLIR; West Malling) and FLIR-Tools-Software (FLIR; West 721 
Malling), to quantify local temperature (Martínez-Sánchez et al., 2017). 722 
Blood and Plasma analysis. Blood was collected from the tail vein of HFD fed mice,  723 
2 h post-injections with PBS, AMPH or PEGyAMPH, without access to food. Blood glucose was 724 
measured with a glucometer (Accu-Check, Roche). Analysis of Insulin, Triglycerides, Glycerol 725 
and FFA levels in plasma was performed by using Mouse Ultrasensitive Insulin ELISA (Alpco), 726 
Triglyceride Quantification Kit (Abcam), Free Glycerol Reagent (Sigma) and Glycerol Standard 727 
Solution (Sigma), and Free Fatty Acid Quantification Kit (MAK044, Sigma), respectively according 728 
. 729 
Tissue NE measurements (ELISA). To assess peripheral NE content in tissues, mice were 730 
sacrificed in ad libitum conditions 2 h post injection with PBS, AMPH or PEGyAMPH. NE levels 731 
were determined with a NE ELISA kit (Labor Diagnostika Nord GmbH). Tissues were 732 
homogenized and sonicated in homogenization buffer (1 M HCl, 1 mM EDTA, 4 mM sodium 733 
metabisulfite), and cellular debris was pelleted by centrifugation at 20,000 g for 10 min at 4 ºC). 734 
All tissue samples were normalized to total tissue protein concentration, measured with Quick 735 
Start Bradford protein assay (Bio- . 736 
Fecal output assay. 24 h fecal output was collected and weighed. The feces were washed with 737 
1x PBS and total triglyceride content was extracted by homogenization and boiling, for 2 cycles 738 
of 5 min, in 5% NP-40. Triglyceride content was measured using Triglyceride Quantification Kit 739 
740 
output. 741 
Tissue Triglycerides Analysis. To assess gastrocnemius muscle and liver content in tissues, 742 
mice were sacrificed in ad libitum conditions 2 h post injection with PBS, AMPH or PEGyAMPH. 743 
Triglyceride content was measured using Triglyceride Quantification Kit (Abcam), according to 744 
Tissue samples were normalized to total tissue protein concentration, 745 






Quantitative PCR. For gene expression analysis mice were sacrificed in ad libitum conditions 2 748 
h post injection with PBS, AMPH or PEGyAMPH, tissues were collected and immediately frozen. 749 
Total tissue RNA was extracted by using PureLink RNA Mini Hit (Invitrogen) according to 750 
, from which complementary DNA was reverse-transcribed by using 751 
SuperScript II (Invitrogen) and random primers (Invitrogen). Quantitative PCR was performed with 752 
SYBR Green (Applied Biosystems) in ABI QuantStudio 7 (Applied Biosystems). Glyceraldehyde 753 
3-phosphate dehydrogenase (GAPDH) was used as housekeeping gene to normalize liver and 754 
gastrocnemius muscle tissue samples. Acidic ribosomal phosphoprotein P0 (Arbp0) was used as 755 
housekeeping gene to normalize adipose tissues samples. The list of primers used is shown in 756 
Supplementary Table 1.  757 
 758 
SCG neurons culture and treatments. Primary cultures of SCG neurons were performed from 759 
postnatal day 30 C57BL/6 or TH-cre; CAG-LSL-GCaMP3 mice (male and female). After 760 
decapitation, both SCG of each animal were removed and cleaned of all visible adipose tissue 761 
and surrounding connective tissue before transfer to Dulbecco's Modified Eagle Medium 762 
(Biowest). Then, SCG were treated enzymatically in two steps to yield single neurons in 763 
accordance to the method described by Motagally and collaborators (Motagally et al., 2009), with 764 
some modifications. First, SCG were subjected to enzymatic dissociation in 2.5 mg/mL 765 
collagenase solution (Sigma-Aldrich) in Hank's Balanced Salt Solution (HBSS) without calcium 766 
and magnesium (Gibco, Life Technologies) at 37 ºC with agitation, followed by 0.25% trypsin 767 
solution (Biowest) in PBS at 37 ºC with agitation. SCG was then mechanically dissociated into a 768 
suspension of single cells. The isolated sympathetic neurons were plated, 2500 cells per coverslip 769 
(6 mm) coated with poly-d-lysine (Sigma) and growth factor-reduced Matrigel (BD Biosciences) 770 
and cultured in Neurobasal medium (Gibco) supplemented with 2% B-27 (Gibco), 10% fetal 771 
bovine serum (Gibco), 1% penicillin/streptomycin (Biowest), 100 ng/mL nerve growth factor (AbD 772 
Serotec) and 5 -fluoro-2'-deoxyuridine (Sigma-Aldrich). Cells were kept in culture for 6 days 773 
in vitro (DIV) at 37 ºC with 5% CO2 conditioned atmosphere to obtain an enriched culture of 774 
 or 15 775 
2 conditioned atmosphere. Butoxamine (Santa-Cruz 776 
Biotechnology) was add at a concentration of , 30min prior to the calcium-imaging 777 
experiments. 778 
Intracellular Calcium-Imaging. For Ca2+ experiments, sympathetic neurons were obtained from 779 
TH-cre; CAG-LSL-GCaMP3 mice. At 7 DIV, coverslips with sympathetic neurons from GCaMP3+ 780 
mice were mounted on an inverted microscope with epifluorescent optics (Axiovert 135TV, Zeiss) 781 
equipped with a xenon lamp (located at a Lambda DG-4, Sutter Instrument) and band-pass filter 782 
of 450-490 nm wavelengths. Ca2+ measurements were performed at 37 ºC, as reported in (Jacob 783 
et al., 2014). Throughout the experiments the Ach was applied focally through a drug-filled 784 
micropipette placed under visual guidance over a single neuronal cell. Drug release was 785 
performed by focal pressure (10 psi for 40 s) through a Toohey Spritzer pressure System Ile 786 
(Toohey Company). Pressure application of external physiological solution did not cause any 787 
measurable change in intracellular Ca2+ concentration. Images were obtained every 250 ms by 788 
exciting the preparations at 450-490 nm and the emission wavelength was set to 510 nm. Neurons 789 





by using the software MetaFluor (Universal Imaging, West Chester, PA). Ca2+ levels were 791 
recorded at the cell body of neurons (manually defined over the cell profile) in the field of view 792 
 = 793 
[(Fpost  Frest)/Frest]). 794 
Electrophysiology. Whole cell patch-clamp recordings performed at 7 DIV in dissociated 795 
cultures of sympathetic neurons from C57BL/6 mice using an upright microscope (Zeiss Axioskop 796 
2FS) equipped with differential interference contrast optics by using a Zeiss AxioCam MRm 797 
camera and a x40 IR-Achroplan objective. During recordings, cells were continuously superfused 798 
with artificial cerebrospinal fluid containing (in mM: 124 NaCl, 3 KCl, 1.2 NaH2PO4, 25 NaHCO3, 799 
2 CaCl2, 1 MgSO4 and 10 glucose), which was continuously gassed with 95% O2/5% CO2. 800 
Recordings were performed at room temperature in current-clamp or voltage-clamp mode 801 
[holding potential (Vh) = -60 mV] with an Axopatch 200B amplifier (Axon Instruments)(Félix-802 
Oliveira et al., 2014)803 
solution (containing (in mM): 125 K-gluconate, 11 KCl, 0.1 CaCl2, 2 MgCl2, 1 EGTA, 10 HEPES, 804 
2 MgATP, 0.3 NaGTP, and 10 phosphocreatine, pH 7.3, adjusted with 1 M NaOH, 280-290 805 
mOsm) were used to record excitatory synaptic currents and action potential activity. The junction 806 
potential was not compensated for, and offset potentials were nulled before gigaseal formation. 807 
The resting membrane potential was measured immediately upon establishing whole cell 808 
configuration. Firing patterns of sympathetic neurons were then immediately assessed in current-809 
clamp mode by injection of 500 ms current pulses (-25 275 pA in 12.5 or 25 pA increments) from 810 
an initial holding potential (811 
generation was determined by membrane potential at which phase plot slope reached 10 mV/ms 812 
(Naundorf et al., 2005). For each neuron,  was calculated as the 813 
difference between the resting membrane potential and the threshold for action potential 814 
generation. 815 
Fourier-transform ion cyclotron resonance (FT-ICR) mass spectrometry. 12 weeks old male 816 
C57BL/6 mice were injected IP and sacrificed 30 min post-injection with AMPH or PEGyAMPH 817 
(dose: 120 µmol/kg of BW for both drugs). Brain samples were snap-frozen in liquid nitrogen 818 
before extraction procedures (Agudelo et al., 2014). Whole brain samples were smashed and 819 
extracted using ice-cold 1 mM perchloric acid (500 µL per sample) and left extracting overnight. 820 
After this time, the samples were centrifuged twice for 20 min at 5000 rpm, 4 ºC. Supernatants 821 
were transferred to new vials, frozen and freeze dried overnight each time, concentrated to 50 822 
µL. Then, 25 µL of the remaining solutions were diluted in 75 µL of an electrospray ionization 823 
solution (CH3CN:H2O, 3:1). The samples were then evaluated through direct injection by using a 824 
Fourier-transform ion cyclotron resonance (FT-ICR) mass spectrometer (Bruker Apex Ultra, 7 825 
Tesla actively shielded magnet).  826 
Quantitative liquid chromatography with mass spectrometry detection. 8-12 weeks old 827 
C57BL/6 mice were injected IP and sacrificed 30 min post-injection with AMPH or PEGyAMPH 828 
(dose: 120 µmol/kg of BW for both drugs). Plasma and tissue samples were snap-frozen in liquid 829 
nitrogen upon collection and extraction procedures were prepared by a protein crash method for 830 
the extraction and quantitative analysis of drug content. Briefly, around 100 mg of tissue (brain 831 
and heart) were added to 100 µL of water inside a plastic screw-cap Eppendorf vial, followed by 832 





100 nM in water). Then a 5 mm stainless steel ball bearing was added to each sample. The 834 
samples were then homogenized using a Bioprep-24-1004 homogenizer (Allsheng, Hangzhou 835 
City, China) run at speed; 5 m/s, time; 30 seconds for 2 cycles. Then, 250 µL of acetone was 836 
added to each sample to precipitate any proteins in the solution. The samples were thoroughly 837 
vortexed to ensure optimal analyte recovery (recovery was >75 %). The samples were then 838 
centrifuged (5 min at ~20,000 g) to produce a clear supernatant separate from any solid particles. 839 
The supernatant was then transferred in to a separate 2 mL amber glass auto-sampler vial 840 
(Agilent Technologies, Santa Clara California, USA). The acetone solvent was then evaporated-841 
off by concentrating the sample on an Eppendorf Concentrator Plus system (Eppendorf, 842 
Stevenage, UK) run for 20 minutes at 60 degree Celsius. The remaining sample (~200 µL) was 843 
-volume vial insert inside a 2 mL amber glass auto-sample vial 844 
ready for liquid chromatography with mass spectrometry detection (LC-MS). Full chromatographic 845 
separation of the analytes (AMPH and PEGyAMPH) was achieved using Shimadzu HPLC System 846 
(Shimadzu UK Limited, Milton Keynes, United Kingdom) with the injection of 5 µL onto a Waters 847 
Acquity UPLC® BEH C18 column; 1.7 µm, I.D. 2.1 mm X 50 mm, maintained at 40 °C. Mobile 848 
phase A was water with 0.1% formic acid. Mobile phase B was acetonitrile with 0.1% formic acid.  849 
The flow was maintained at 500 µL per minute through the following gradient: 0.00 minutes_1% 850 
mobile phase B; 1.00 min, 1% mobile phase B; 2.00 min, 95% mobile phase B; 3.30 min, 95% 851 
mobile phase B; 3.40 min, 1% mobile phase B; 6.50 min, 1% mobile phase B. The sample 852 
injection needle was washed using acetonitrile with 0.1 % formic acid. The mass spectrometer 853 
(MS) used was the Thermo Scientific Exactive Orbitrap with a heated electrospray ionization 854 
source (Thermo Fisher Scientific, Hemel Hempstead, UK). The mass spectrometer was calibrated 855 
immediately before sample analysis using positive and negative ionization calibration solution 856 
(recommended by Thermo Scientific). Additionally, the heated electrospray ionization source tune 857 
files were optimized for both AMPH and PEGyAMPH independently and applied to the mass 858 
spectrometry method by segmenting the MS method; this produced the lowest limit of quantitation 859 
for each compound. AMPH segment 1 was run in positive mode from 0 to 2.9 minutes with the 860 
mass spectrometer resolution set to 50,000 with a full-scan range of m/z 60 to 1200 Da. 861 
PEGyAMPH segment 2 was run in positive mode from 2.9 to 5 minutes with the mass 862 
spectrometer resolution set to 50,000 with a full-scan range of m/z 60 to 1200 Da. Analyte 863 
quantification was achieved by extracting the expected analyte masses (AMPH: 136.11208 864 
[M+H]+ and 119.0861 [M+H-NH3]+ at retention time 2.73 minutes; AMPH-d11: 147.18112 [M+H]+ 865 
and 130.1551 [M+H-NH3]+ at retention time 2.72 minutes; PEGyAMPH: 354.22750 [M+H]+ at 866 
retention time 3.12 minutes). The area under the curve of these high resolution extracted ion 867 
chromatograms (with a window of ± 8 ppm) were normalized to the internal standard 868 
(amphetamine-d11) to account for extraction and instrument variations and then compared to a 869 
quantitative calibration line (lower limit of quantitation: 10 nM; upper limit of quantitation: 1,000 870 
nM, for both compounds). The calculated concentrations of the analytes were then divided by the 871 
amount of tissue used in the extraction protocol to give the final results in nM per mg of tissue 872 





























Histopathological analyses. Mouse tissues were fixed in buffered formalin, and inclusion in 898 
paraffin was done according to standard technical procedures. Histopathology studies were 899 
performed on formalin-fixed and paraffin-embedded sections of 3 6 m thick for Haematoxylin 900 
and Eosin. Tissues were analysed with a Leica DM LB2 microscope, and images captured with a 901 
Leica DFC 250 camera. 902 
Statistics. The number of animals used in each experimental setting and the analysis performed 903 
are specified in each figure legend. Statistical analyses were performed with GraphPad Prism 904 
t-test (two-tailed) when two groups were being 905 
compared or one-way ANOVA when several groups were being compared. One-way ANOVA was 906 
followed by was followed by Bonferroni multiple-comparisons test with one group indicated as a 907 
control group. p< 0.05 was considered statistically significant. Data are represented as mean ± 908 
S.E.M. Data displayed normal variance. 909 
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Figure S1. The sympathomimetic action of AMPH is required for its anti-obesity effect and the 1101
elevation of lipolysis. A. Levels of TH mRNA expression, in the superior cervical ganglia (SCG) and in 1102
the adrenal glands of Control and Symp mice, determined by qRT-PCR relative to the housekeeping gene 1103
GAPDH. B. Body weight of Control (left) and Symp (right) mice during 6 weeks of HFD exposure and PBS 1104
or AMPH treatment (dose: 120µmol/kg of BW, daily IP injections). C. Plasma Triglycerides (TGs), Free 1105
Fatty Acids (FFAs) and Glycerol content in HFD fed Control and Symp mice 2h post-injection without access 1106
to food. (*p<0.05; **p<0.01; ###p<0.001;
 
n = 6-12. t-test, with Holm-1107
Sidak correction method. *PBS vs AMPH; #Control versus Symp). Data presented as mean ± S.E.M. 1108








Figure S2. PEGylation of AMPH reduces excretion and alters its pharmacological properties. A. Time 1113
course of the plasma concentration of AMPH or PEGyAMPH, post IV injection (dose: 120 µmol/kg of BW), 1114
assessed by mass spectrometry. B-C. Time course of the concentration of AMPH or PEGyAMPH, in the 1115
liver (B) and in the urine (C) of C57BL/6. D. Summary of in vitro radioligand ([3H]nisoxetine) competition 1116
assays with AMPH and with PEGyAMPH (0,5µM) for the binding to Slc6a2. Data presented as mean ± 1117








Figure S3. PEGyAMPH facilitates SNS activation and increases NE availability in target tissues.  1122
A. Resting membrane potential. B. AP firing threshold and C.  of Vehicle, 1123
AMPH and PEGyAMPH-treated neurons (*p<0.05;
 
**p<0.01; *** p<0.001; n = 8; Statistics done using one-1124
way ANOVA followed by Bonferroni correction). D. 3D structure of 1-adrenoceptor in complex with AMPH 1125
and PEGyAMPH. Left: Minimized structure calculated by Molecular Mechanics (MM) for 1-1126
adrenoceptor/AMP complex, showing the most relevant interactions between AMP and the receptor. Right: 1127
Minimized structure calculated by MM for 1-adrenoceptor/PEGyAMP complex, showing the most relevant 1128
interactions ligand-receptor. The receptor is represented as white ribbons and the carbon atoms of the 1129
residues of the receptor that are interacting directly with the ligands are in blue. The carbon atoms of the 1130
ligands are in green. and in the E. NE content in the Liver and F. NE content in gonadal and inguinal White 1131
Adipose Tissue (gWAT and iWAT, respectively) of C57BL/6 mice 3-4h post-injection, with PBS, AMPH and 1132
PEGyAMPH (dose: 120 µmol/kg of BW for both drugs, IP). G. BW of C57BL/6 mice exposed to HFD and 1133
treatment with PBS or two different doses of PEGyAMPH (0,06 and 120 µmol/kg of BW, daily IP injections).  1134





with Holm-Sidak correction. *PBS versus PEGyAMPH; #PBS versus AMPH; AMPH versus PEGyAMPH.) 1136 






Figure S4. PEGyAMPH, unlike AMPH, does not affect cardiovascular function. A. Breath Rate and 1139
Heart Rate measured under anaesthesia (1-2% isoflurane) using a CC-Sensor for pulse-oximetry, before 1140
and 30-45min post IP injection with PEGyAMPH or AMPH (dose: 120 µmol/kg of BW for both drugs). B. 1141
Drug concentration in the Heart of C57BL/6 mice injected post IP injection (dose: 120 µmol/kg of BW for 1142
both drugs), assessed by mass spectrometry. C. Heart NE content measured 30 min post IP injection. D. 1143
Breath Rate and Heart Rate measured before and 15-30min post ICV injection with either PBS, AMPH or 1144
PEGyAMPH (bolus of 60nmol, per animal) of C57BL/6 mice. (#,$, p<0.05; $$, , p<0.01,
 
$$$, p<0.001, 1145
####,$$$$p<0.0001; n = 8-12. t-test, with Holm-Sidak correction 1146
method. #PBS vs AMPH; AMPH versus PEGyAMPH; $Baseline versus AMPH; Baseline versus 1147






Figure S5. PEGyAMPH improves insulin sensitivity by increasing EE, without affecting Locomotor 1150
Activity (LA). A. Blood Glucose and B. Plasma Insulin levels, C. Pancreatic NE content. D. Liver gene 1151
expression levels of IR and gluconeogenic genes Glucose 6-phosphatase (G-6-Pase) and 1152
Phosphoenolpyruvate carboxykinase (PEPCK) determined by qRT-PCR relative to housekeeping gene 1153
GAPDH, of fed mice 2 h post injection and without access to food, after 10 weeks of HFD exposure and 1154





weeks of HFD exposure and respective treatment E and G. Intraperitoneal Glucose Tolerance Test (GTT, 1156 
glucose bolus of 2g/kg of BW) performed 6h post injection with PBS, AMPH or PEGyAMPH without access 1157 
to food, and the respective AUC for 120min blood glucose levels. F and H. Insulin Tolerance Test (ITT, 1158 
insulin bolus of 0.9U/kg of BW) performed 2h post injection with PBS, AMPH or PEGyAMPH (dose: 120 1159 
µmol/kg of BW for both drugs) without access to food, and the respective AUC for 180min blood glucose 1160 
levels. I. Relation between the average EE and total body mass. J. Cumulative Locomotor Activity (LA) 1161 
measured for 72h, represented in beam breaks counts. (*,#; p<0.05, **,##p<0.01; ####p<0.0001, n = 8-15. 1162 
-test, with Holm-Sidak correction method. *PBS versus 1163 
PEGyAMPH; #PBS versus AMPH; PEGyAMPH versus AMPH.) Data presented as mean ± S.E.M. Related 1164 






Figure S6. PEGyAMPH elevates peripheral lipid utilization during DIO. (A-C and G) Liver and (D-F and 1167
H) Muscle measurements from fed C57BL/6 mice after 10 weeks of HFD exposure and chronic treatment 1168
with PBS, AMPH or PEGyAMPH. A. NE, B. TGs and C. Glycogen content in the liver and D. NE, E. TGs 1169
and F. Glycogen content in muscle, all values were normalized to total protein levels. G. Liver mRNA levels 1170
of Fatty Acid Transporter (FAT), Lipoprotein Lipase (LPL) and Fatty Acid Synthase (FAS) determined by 1171
qRT-PCR relative to housekeeping gene GAPDH. H. Muscle mRNA levels of ADRB3, LPL, FAT, HSL and 1172
AtgL determined by qRT-PCR relative to housekeeping gene GAPDH. (*, p<0.05; **,##p<0.01; 1173
###; p<0.001; ****,####p<0.0001;
 
n = 12. t-test, with Holm-Sidak 1174
correction. *PBS versuss PEGyAMPH; #PBS versus AMPH; PEGyAMPH versus AMPH.) Data presented 1175






Figure S7. PEGyAMPH increases Thermogenesis during DIO. A. BAT mRNA levels of the Insulin 1178
Receptor (IR) and of the Glucose Transporter type 4 isoform (GLUT4) and B. iWAT mRNA levels of 1179
thermogenic genes, gene expression was determined by determined by qRT-PCR, relative to 1180
housekeeping gene Arbp0. C. Representative Histologic Slices of BAT stained with H&E and D. 1181
Quantification of BAT Adipocyte Size of C57BL/6 mice after 10 weeks of HFD exposure and treatment with 1182
PBS, AMPH or PEGyAMPH (dose: 120 µmol/kg of BW for both drugs, daily IP injections). E. Daily Food 1183
Intake of C57BL/6 mice mice exposed to HFD and treatment with PBS, AMPH or PEGyAMPH (dose: 120 1184
µmol/kg of BW for both drugs, daily IP injections) under thermoneutral housing conditions. F. Schematic 1185
summary of the mechanism of action for anti-obesity treatment of the two sympathomimetics used in this 1186
study. (*,#p<0.05; **,##p<0.01, ####, p<0.0001 n = 5-12. t-test, 1187
with Holm-Sidak correction. *PBS versus PEGyAMPH; #PBS versus AMPH, AMPH versus PEGyAMPH.) 1188





Table S1. List of qPCR primers: 1190 
Primer Sequence 
Arbp0 Fwd 5´ CTTTGGGCATCACCACGAA 3´ 
Arbp0 Rev 5´ GCTGGCTCCCACCTTGTCT 3´ 
GAPDH Fwd 5´ AACTTTGGCATTGTGGAAGG 3´ 
GAPDH Rev 5´ ACACATTGGGGGTAGGAACA 3´ 
IR Fwd  
IR Rev  
GLUT4 Fwd  
GLUT4 Rev  
G-6-Pase Fwd  
G-6-Pase Rev  
PEPCK Fwd  
PEPCK Rev  
ADRB3 Fwd  
ADRB3 Rev  
AtgL Fwd  
AtgL Rev  
HSL Fwd  
HSL Rev  
LPL Fwd  
LPL Rev  
FAS Fwd  
FAS Rev  
FAT/CD36 Fwd  
FAT/CD36 Rev  
Ucp1 Fwd  
Ucp1 Rev  
Pgc1a Fwd  
Pgc1a Rev  
PRDM16 Fwd  
PRDM16 Rev  
CIDEA Fwd  
CIDEA Rev  
cox8b Fwd  
cox8b Rev  
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